Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stapokibart in uncontrolled seasonal allergic rhinitis
NCT05470647Phase 2Completed
- Sponsor
- Beijing Tongren Hospital
- Start
- Aug 2022
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of stapokibart in seasonal allergic rhinitis (SAR), sponsored by Beijing Tongren Hospital. Started Aug 2022; status: completed.
02
Drugs
stapokibart
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT05470647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05470647.